Alphabet’s Secret AI Weapon Could Cure Diseases Faster Than Ever
LONDON, UK, 17TH APRIL 2025–Isomorphic Labs, a subsidiary of Alphabet, unveiled NVIDIA’s DGX Cloud and BioNeMo frameworks in a new AI-driven overhaul for the company’s drug discovery platform.
The change promises to alter the pathways through which life-saving medicines can be developed.
The company founded by DeepMind CEO Demis Hassabis is currently integrating NVIDIA’s generative AI models.
These models facilitate the mapping of molecular interactions, providing faster-than-expected results from laboratory testing and experimentation.
Isomorphic Labs seeks to diminish the timeline for drug development to mere months instead of years.
“In drug discovery, we’re building an all-inclusive digital twin. ‘This technology allows biology to be better understood through AI.’”
Demis Hassbis, the company’s CEO said.
The firm together with a growing drug candidate portfolio and partnerships in the works are scaling their compute infrastructure with NVIDIA’s DGX Cloud to conduct thousands of experiments at the same time.
This digital-first lab model aims to fuse AI imagination and the pharmaceutical industry.
“Isomorphic Labs is leading humanity into new frontiers- We are witnessing AI estimate the accuracy in simulation of drug-target interactions with astonishing precision,”
Said Kimberly Powell, The Health Sector Vice President at NVIDIA
This program is a substantiation of props getting together forming part of a larger picture of Alphabet’s intentions of incorporating AI into Healthcare.
In Isomorphic Labs’ case, new pharmaceutical collaborations as well as development of consigned clinical studies are likely to emerge in tandem guiding updates which should remain on schedule.
Accelya Launches FLX ONE Cargo to Revolutionize Air Cargo Tech
Infosys and Spark Join Forces for AI-Driven Transformation
NVIDIA’s Blackwell Ultra: The AI Leap That Changes Everything
